Chemed Corp (CHE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Chemed Corp stock (CHE) is currently trading at $374.02. Chemed Corp PE ratio is 20.36. Chemed Corp PS ratio (Price-to-Sales) is 2.08. Analyst consensus price target for CHE is $443.00. WallStSmart rates CHE as Underperform.
- CHE PE ratio analysis and historical PE chart
- CHE PS ratio (Price-to-Sales) history and trend
- CHE intrinsic value — DCF, Graham Number, EPV models
- CHE stock price prediction 2025 2026 2027 2028 2029 2030
- CHE fair value vs current price
- CHE insider transactions and insider buying
- Is CHE undervalued or overvalued?
- Chemed Corp financial analysis — revenue, earnings, cash flow
- CHE Piotroski F-Score and Altman Z-Score
- CHE analyst price target and Smart Rating
Chemed Corp
📊 No data available
Try selecting a different time range
CHE Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Chemed Corp (CHE)
CHE trades 271% above its Graham fair value of $124.85, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Chemed Corp (CHE) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, institutional own.. Concerns around price/book and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Chemed Corp (CHE) Key Strengths (3)
Every $100 of shareholder equity generates $25 in profit
104.43% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Chemed Corp (CHE) Areas to Watch (7)
Revenue declining -0.10%, a shrinking business
Earnings declining -9.10%, profits shrinking
Very expensive at 5.3x book value
Growth is fairly priced, not cheap, not expensive
Decent operational efficiency, solid but not exceptional
Revenue is fairly priced at 2.08x sales
Decent profitability, keeps $11 per $100 revenue
Chemed Corp (CHE) Detailed Analysis Report
Overall Assessment
This company scores 51/100 in our Smart Analysis, earning a C- grade. Out of 10 metrics analyzed, 3 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 3.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, Institutional Own., Market Cap. Profitability is solid with Return on Equity at 25.30%.
The Bear Case
The primary concerns are Revenue Growth, EPS Growth, Price/Book. Some valuation metrics including PEG Ratio (1.60), Price/Sales (2.08), Price/Book (5.31) suggest expensive pricing. Growth concerns include Revenue Growth at -0.10%, EPS Growth at -9.10%, which may limit upside. Profitability pressure is visible in Operating Margin at 16.60%, Profit Margin at 10.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 25.30% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -0.10% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Return on Equity, Institutional Own.) and negatives (Revenue Growth, EPS Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CHE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CHE's Price-to-Sales ratio of 2.08x trades 95% above its historical average of 1.07x (87th percentile), historically expensive. The current valuation is 24% below its historical high of 2.75x set in May 2018, and 396% above its historical low of 0.42x in Apr 2008. Over the past 12 months, the PS ratio has compressed from ~2.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Chemed Corp (CHE) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Chemed Corp faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 2.5B with 10% decline year-over-year. Profit margins of 10.5% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 2530.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 117M in free cash flow and 134M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 10% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Margin expansion: can Chemed Corp push profit margins above 15% as the business scales?
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Chemed Corp.
Bottom Line
Chemed Corp faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(31 last 3 months)
| Insider | Type | Shares |
|---|---|---|
MCNAMARA, KEVIN J Director, president and CEO | Sell | -2,000 |
Data sourced from SEC Form 4 filings
Last updated: 8:27:09 AM
About Chemed Corp(CHE)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Chemed Corporation provides hospice and hospice services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers across the United States. The company is headquartered in Cincinnati, Ohio.